5/27 Late treatment study
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment.
NCT04292899
Goldman et al., 5/27/2020, peer-reviewed, 26 authors.
Please send us corrections, updates, or comments.
Submit